Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma

OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...